Skip to main content
SpringerLink
Log in

Impact of skeletal complications on patients’ quality of life, mobility, and functional independence

  • Review Article
  • Published:
Supportive Care in Cancer Aims and scope Submit manuscript

An Erratum to this article was published on 15 August 2008

Abstract

Introduction

Skeletal-related events (SREs) from malignant bone disease cause considerable morbidity and can dramatically reduce patients’ quality of life.

Discussion

Pathologic fractures often require surgical intervention and palliative radiotherapy. Thus, patients suffer impaired mobility, loss of functional independence, and diminished health-related quality of life (HRQOL). Bisphosphonates can delay the onset and reduce the incidence of SREs and have become the standard of care for the treatment of malignant bone disease; however, minimal information on the effects of bisphosphonate treatment on HRQOL is available. Targeted HRQOL assessments for patients with malignant bone disease are currently under development and are discussed herein.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC et al (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365–376

    Article  PubMed  CAS  Google Scholar 

  2. Adrover E, Allepuz J, Sureda A, Domine M, Barnadas A, Constela M, Lluch A, Ruiz M, Piera J, Mayordomo JI, Morales A, Muñoz M, Alcover J, Colomer R, Llombart A, Massutti B, Carballido J, Garrido R, Garcia R, Badia X, Lizan L, Gilabert M (2005) Development of a questionnaire to measure health-related quality of life (HRQoL) in patients with bone metastases (BOMET-QoL). J Outcomes Res 9:15–27

    Google Scholar 

  3. Arianayagam M, Chang J, Rashid P (2007) Chemotherapy in the treatment of prostate cancer—is there a role? Aust Fam Physician 36:737–739

    PubMed  Google Scholar 

  4. Aus G, Abbou CC, Bolla M, Heidenreich A, Schmid HP, van Poppel H, Wolff J, Zattoni F (2005) EAU guidelines on prostate cancer. Eur Urol 48:546–551

    Article  PubMed  CAS  Google Scholar 

  5. Bang SM, Park SH, Kang HG, Jue JI, Cho IH, Yun YH, Cho EK, Shin DB, Lee JH (2005) Changes in quality of life during palliative chemotherapy for solid cancer. Support Care Cancer 13:515–521

    Article  PubMed  Google Scholar 

  6. Barkin RL, Barkin SJ, Barkin DS (2005) Perception, assessment, treatment, and management of pain in the elderly. Clin Geriatr Med 21:465–490, v

    Article  PubMed  Google Scholar 

  7. Berenson JR, Hillner BE, Kyle RA, Anderson K, Lipton A, Yee GC, Biermann JS (2002) American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma. J Clin Oncol 20:3719–3736

    Article  PubMed  Google Scholar 

  8. Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, George S, Lipton A, Keller A, Ballester O, Kovacs M, Blacklock H, Bell R, Simeone JF, Reitsma DJ, Heffernan M, Seaman J, Knight RD (1998) Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. J Clin Oncol 16:593–602

    PubMed  CAS  Google Scholar 

  9. Berry DL, Moinpour CM, Jiang CS, Ankerst DP, Petrylak DP, Vinson LV, Lara PN, Jones S, Taplin ME, Burch PA, Hussain MHA, Crawford ED (2006) Quality of life and pain in advanced stage prostate cancer: results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone. J Clin Oncol 24:2828–2835

    Article  PubMed  CAS  Google Scholar 

  10. Bianchi ML, Orsini MR, Saraifoger S, Ortolani S, Radaelli G, Betti S (2005) Quality of life in post-menopausal osteoporosis. Health Qual Life Outcomes 3:78

    Article  PubMed  Google Scholar 

  11. Body JJ, Diel IJ, Bell R, Pecherstorfer M, Lichinitser MR, Lazarev AF, Tripathy D, Bergstrom B (2004) Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer. Pain 111:306–312

    Article  PubMed  CAS  Google Scholar 

  12. Body JJ, Diel IJ, Lichinitser MR, Kreuser ED, Dornoff W, Gorbunova VA, Budde M, Bergstrom B (2003) Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol 14:1399–1405

    Article  PubMed  Google Scholar 

  13. Bogardus ST Jr, Towle V, Williams CS, Desai MM, Inouye SK (2001) What does the medical record reveal about functional status? A comparison of medical record and interview data. J Gen Intern Med 16:728–736

    Article  PubMed  Google Scholar 

  14. Cancer Research UK (2007) Bone mets newsletter 03: April 2007. Available at: http://www.ucl.ac.uk/cancertrials/trials/rib/Spring%2007.pdf. Accessed December 20, 2007

  15. Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, Silberman M, Yellen SB, Winicour P, Brannon J et al (1993) The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol 11:570–579

    PubMed  CAS  Google Scholar 

  16. Chow E, Wu JS, Hoskin P, Coia LR, Bentzen SM, Blitzer PH (2002) International consensus on palliative radiotherapy endpoints for future clinical trials in bone metastases. Radiother Oncol 64:275–280

    Article  PubMed  Google Scholar 

  17. Cleeland CS, Ryan KM (1994) Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singapore 23:129–138

    PubMed  CAS  Google Scholar 

  18. Clemons M, Dranitsaris G, Ooi W, Cole DE (2007) A phase II trial evaluating the palliative benefit of second-line oral ibandronate in breast cancer patients with either a skeletal related event (SRE) or progressive bone metastases (BM) despite standard bisphosphonate (BP) therapy. Breast Cancer Res Treat [Epub ahead of print]

  19. Clemons MJ, Dranitsaris G, Ooi WS, Yogendran G, Sukovic T, Wong BY, Verma S, Pritchard KI, Trudeau M, Cole DE (2006) Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy. J Clin Oncol 24:4895–4900

    Article  PubMed  CAS  Google Scholar 

  20. Coleman RE (1997) Skeletal complications of malignancy. Cancer 80(suppl):1588–1594

    Article  PubMed  CAS  Google Scholar 

  21. Coleman RE (2004) Bisphosphonates: clinical experience. Oncologist 9(suppl 4):14–27

    Article  PubMed  CAS  Google Scholar 

  22. Cook RJ, Major P (2001) Methodology for treatment evaluation in patients with cancer metastatic to bone. J Natl Cancer Inst 93:534–538

    Article  PubMed  CAS  Google Scholar 

  23. Deschamps M, Band PR, Coldman AJ (1988) Assessment of adult cancer pain: shortcomings of current methods. Pain 32:133–139

    Article  PubMed  CAS  Google Scholar 

  24. Diel IJ (2007) Effectiveness of bisphosphonates on bone pain and quality of life in breast cancer patients with metastatic bone disease: a review. Support Care Cancer 15:1243–1249

    Article  PubMed  Google Scholar 

  25. Diel IJ, Body JJ, Lichinitser MR, Kreuser ED, Dornoff W, Gorbunova VA, Budde M, Bergstrom B (2004) Improved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer. Eur J Cancer 40:1704–1712

    Article  PubMed  CAS  Google Scholar 

  26. Eastham J, McKiernan J, Gleason D, Zheng M, Saad F Effect of zoledronic acid on bone pain and skeletal morbidity in patients with advanced prostate cancer: analysis by baseline pain [poster]. Presented at: 41st Annual Meeting of the American Society of Clinical Oncology; May 13–17, 2005; Orlando, Florida. Abstract 4561

  27. Efstathiou E, Bozas G, Kostakopoulos A, Kastritis E, Deliveliotis C, Antoniou N, Skarlos D, Papadimitriou C, Dimopoulos MA, Bamias A (2005) Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment. Urology 65:126–130

    Article  PubMed  CAS  Google Scholar 

  28. Elomaa I, Kylmala T, Tammela T, Viitanen J, Ottelin J, Ruutu M, Jauhiainen K, Ala-Opas M, Roos L, Seppanen J et al (1992) Effect of oral clodronate on bone pain. A controlled study in patients with metastatic prostatic cancer. Int Urol Nephrol 24:159–166

    Article  PubMed  CAS  Google Scholar 

  29. Ernst DS, Tannock IF, Winquist EW, Venner PM, Reyno L, Moore MJ, Chi K, Ding K, Elliott C, Parulekar W (2003) Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain. J Clin Oncol 21:3335–3342

    Article  PubMed  CAS  Google Scholar 

  30. European Organisation for Research and Treatment of Cancer (2007) EORTC Quality of Life Group projects. Available at: http://www.eortc.be/home/qol/QLGProjects.htm. Accessed July 31, 2007

  31. EuroQol Group (1990) EuroQol—a new facility for the measurement of health-related quality of life. Health Policy 16:199–208

    Article  Google Scholar 

  32. Fulfaro F, Casuccio A, Ticozzi C, Ripamonti C (1998) The role of bisphosphonates in the treatment of painful metastatic bone disease: a review of phase III trials. Pain 78:157–169

    Article  PubMed  CAS  Google Scholar 

  33. Fulfaro F, Leto G, Badalamenti G, Arcara C, Cicero G, Valerio MR, Di Fede G, Russo A, Vitale A, Rini GB, Casuccio A, Intrivici C, Gebbia N (2005) The use of zoledronic acid in patients with bone metastases from prostate carcinoma: effect on analgesic response and bone metabolism biomarkers. J Chemother 17:555–559

    PubMed  CAS  Google Scholar 

  34. Harris K, Chow E (2006) Bone metastases module. Available at: http://www.eortc.be/home/qol/Presentations%20of%20past%20meetings/Southampton%20Nov%202006/Chow_Bone_mets_module_short_Nov2006.pdf. Accessed July 31, 2007

  35. Heidenreich A, Elert A, Hofmann R (2002) Ibandronate in the treatment of prostate cancer associated painful osseous metastases. Prostate Cancer Prostatic Dis 5:231–235

    Article  PubMed  CAS  Google Scholar 

  36. Heidenreich A, Hofmann R, Engelmann UH (2001) The use of bisphosphonate for the palliative treatment of painful bone metastasis due to hormone refractory prostate cancer. J Urol 165:136–140

    Article  PubMed  CAS  Google Scholar 

  37. Heidenreich A, Ohlmann C, Olbert P, Hegele A (2003) High-dose ibandronate is effective and well tolerated in the treatment of pain and hypercalcaemia due to metastatic urologic cancer [abstract]. Eur J Cancer Suppl 1(suppl):S270 Abstract 897

    Article  Google Scholar 

  38. Hering F, Rodrigues PRT, Lipay M (2003) Clodronate for treatment of bone metastases in hormone refractory prostate cancer. Int Braz J Urol 29:228–233

    Article  PubMed  Google Scholar 

  39. Hillner BE, Ingle JN, Chlebowski RT, Gralow J, Yee GC, Janjan NA, Cauley JA, Blumenstein BA, Albain KS, Lipton A, Brown S (2003) American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 21:4042–4057

    Article  PubMed  CAS  Google Scholar 

  40. Hortobagyi GN, Theriault RL, Lipton A, Porter L, Blayney D, Sinoff C, Wheeler H, Simeone JF, Seaman JJ, Knight RD, Heffernan M, Mellars K, Reitsma DJ (1998) Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group. J Clin Oncol 16:2038–2044

    PubMed  CAS  Google Scholar 

  41. Hoskin PJ (2004) The RIB trial. Clin Oncol (R Coll Radiol) 16:445–446

    CAS  Google Scholar 

  42. Jagdev SP, Purohit OP, Heatley S, Herling C, Coleman RE (2001) Comparison of the effects of intravenous pamidronate and oral clodronate on symptoms and bone resorption in patients with metastatic bone disease. Ann Oncol 12:1433–1438

    Article  PubMed  CAS  Google Scholar 

  43. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ (2006) Cancer statistics, 2006. CA Cancer J Clin 56:106–130

    PubMed  Google Scholar 

  44. Kinnane N (2007) Burden of bone disease. Eur J Oncol Nurs 11(suppl 2):S28–S31

    Article  PubMed  Google Scholar 

  45. Kohno N, Aogi K, Minami H, Nakamura S, Asaga T, Iino Y, Watanabe T, Goessl C, Ohashi Y, Takashima S (2005) Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol 23:3314–3321

    Article  PubMed  CAS  Google Scholar 

  46. Lips P, van Schoor NM (2005) Quality of life in patients with osteoporosis. Osteoporos Int 16:447–455

    Article  PubMed  Google Scholar 

  47. Lipton A (2005) Management of bone metastases in breast cancer. Curr Treat Options Oncol 6:161–171

    Article  PubMed  Google Scholar 

  48. Lipton A, Theriault RL, Hortobagyi GN, Simeone J, Knight RD, Mellars K, Reitsma DJ, Heffernan M, Seaman JJ (2000) Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer 88:1082–1090

    Article  PubMed  CAS  Google Scholar 

  49. Mancini I, Dumon JC, Body JJ (2004) Efficacy and safety of ibandronate in the treatment of opioid-resistant bone pain associated with metastatic bone disease: a pilot study. J Clin Oncol 22:3587–3592

    Article  PubMed  CAS  Google Scholar 

  50. Mayer EL, Burstein HJ (2007) Chemotherapy for metastatic breast cancer. Hematol Oncol Clin North Am 21:257–272

    Article  PubMed  Google Scholar 

  51. Menssen HD, Sakalova A, Fontana A, Herrmann Z, Boewer C, Facon T, Lichinitser MR, Singer CR, Euller-Ziegler L, Wetterwald M, Fiere D, Hrubisko M, Thiel E, Delmas PD (2002) Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma. J Clin Oncol 20:2353–2359

    Article  PubMed  CAS  Google Scholar 

  52. O'Rourke N, McCloskey E, Houghton F, Huss H, Kanis JA (1995) Double-blind, placebo-controlled, dose–response trial of oral clodronate in patients with bone metastases. J Clin Oncol 13:929–934

    PubMed  Google Scholar 

  53. Ozyuvaci E, Altan A, Demir C (2005) [The effects of clodronate for the pain treatment of bone metastasis due to prostate cancer]. Agri 17:49–53

    PubMed  Google Scholar 

  54. Pande I, Scott DL, O'Neill TW, Pritchard C, Woolf AD, Davis MJ (2006) Quality of life, morbidity, and mortality after low trauma hip fracture in men. Ann Rheum Dis 65:87–92

    Article  PubMed  CAS  Google Scholar 

  55. Ripamonti C, Fagnoni E, Campa T, Giardina V, Brunelli C, De Conno F (2006) Pain on movement and pain on rest decrease after zoledronic acid infusion in patients with bone metastases due to breast or prostate cancer [abstract]. J Clin Oncol 24(suppl):694s Abstract 18582

    Google Scholar 

  56. Rodrigues P, Hering F, Campagnari JC (2004) Use of bisphosphonates can dramatically improve pain in advanced hormone-refractory prostate cancer patients. Prostate Cancer Prostatic Dis 7:350–354

    Article  PubMed  CAS  Google Scholar 

  57. Rosen LS, Gordon D, Tchekmedyian NS, Yanagihara R, Hirsh V, Krzakowski M, Pawlicki M, De Souza P, Zheng M, Urbanowitz G, Reitsma D, Seaman J (2004) Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial. Cancer 100:2613–2621

    Article  PubMed  CAS  Google Scholar 

  58. Saad F, Gleason D, Murray R, Venner P, Tchekmedyian NS, Lacombe L, Chin J, Vinholes J, Goas JA, Chen B-L, Seaman J (2003) Zoledronic acid is well tolerated for up to 24 months and significantly reduces skeletal complications in patients with advanced prostate cancer metastatic to bone [poster]. Presented at: American Urological Association Annual Meeting; April 26–May 1, 2003; Chicago, Illinois. Abstract 1472

  59. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin JL, Vinholes JJ, Goas JA, Chen B (2002) A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 94:1458–1468

    PubMed  CAS  Google Scholar 

  60. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin JL, Vinholes JJ, Goas JA, Zheng M (2004) Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 96:879–882

    Article  PubMed  CAS  Google Scholar 

  61. Santangelo A, Testai M, Barbagallo P, Manuele S, Di Stefano A, Tomarchio M, Trizzino G, Musumeci G, Panebianco P, Maugeri D (2006) The use of bisphosphonates in palliative treatment of bone metastases in a terminally ill, oncological elderly population. Arch Gerontol Geriatr 43:187–192

    Article  PubMed  CAS  Google Scholar 

  62. Small EJ, Smith MR, Seaman JJ, Petrone S, Kowalski MO (2003) Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. J Clin Oncol 21:4277–4284

    Article  PubMed  CAS  Google Scholar 

  63. Sonoo H, Shimozuma K, Kurebayashi J, Ohta K, Kiyono T (1995) [Systemic therapy, pain relief and quality of life of breast cancer patients with bone metastasis]. Gan To Kagaku Ryoho 22(suppl 1):10–15

    PubMed  Google Scholar 

  64. Spitzer WO, Dobson AJ, Hall J, Chesterman E, Levi J, Shepherd R, Battista RN, Catchlove BR (1981) Measuring the quality of life of cancer patients: a concise QL-index for use by physicians. J Chronic Dis 34:585–597

    Article  PubMed  CAS  Google Scholar 

  65. Stanculeanu DL, Minea LN, Cringeaunu A, Anghel R (2006) Zoledronic acid treatment in osteocondensant bone metastasis prostate cancer patients [abstract]. Presented at: 2006 ASCO Prostate Cancer Symposium; February 24–26, 2006; San Francisco, California. Abstract 289

  66. Sureda A, Isla D, Cozar JM, Ruiz M, Domine M, Margeli M, Adrover E, Ramos M, Pastor M, Martin A, Llombart A, Massutti B, Munoz M, Barnadas A, Fernandez J, Colomer R, Allepuz J, Gilabert M, Badia X (2007) Final development and validation of the BOMET-QoL questionnaire for assessing quality of life in patients with malignant bone disease due to neoplasia. J Med Econ 10:27–39

    Google Scholar 

  67. Theriault RL, Lipton A, Hortobagyi GN, Leff R, Gluck S, Stewart JF, Costello S, Kennedy I, Simeone J, Seaman JJ, Knight RD, Mellars K, Heffernan M, Reitsma DJ (1999) Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. J Clin Oncol 17:846–854

    PubMed  CAS  Google Scholar 

  68. Tidermark J, Zethraeus N, Svensson O, Tornkvist H, Ponzer S (2002) Femoral neck fractures in the elderly: functional outcome and quality of life according to EuroQol. Qual Life Res 11:473–481

    Article  PubMed  Google Scholar 

  69. Trombetti A, Herrmann F, Hoffmeyer P, Schurch MA, Bonjour JP, Rizzoli R (2002) Survival and potential years of life lost after hip fracture in men and age-matched women. Osteoporos Int 13:731–737

    Article  PubMed  CAS  Google Scholar 

  70. Tubiana-Hulin M, Beuzeboc P, Mauriac L, Barbet N, Frenay M, Monnier A, Pion JM, Switsers O, Misset JL, Assadourian S, Bessa E (2001) Double-blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases. Bull Cancer 88:701–707

    PubMed  CAS  Google Scholar 

  71. Vassiliou V, Kalogeropoulou C, Christopoulos C, Solomou E, Leotsinides M, Kardamakis D (2007) Combination ibandronate and radiotherapy for the treatment of bone metastases: clinical evaluation and radiologic assessment. Int J Radiat Oncol Biol Phys 67:264–272

    PubMed  CAS  Google Scholar 

  72. Vassiliou V, Kalogeropoulou C, Giannopoulou E, Leotsinidis M, Tsota I, Kardamakis D (2007) A novel study investigating the therapeutic outcome of patients with lytic, mixed and sclerotic bone metastases treated with combined radiotherapy and ibandronate. Clin Exp Metastasis 24:169–178

    Article  PubMed  CAS  Google Scholar 

  73. Vinholes JJF, Purohit OP, Abbey ME, Eastell R, Coleman RE (1997) Relationships between biochemical and symptomatic response in a double-blind randomised trial of pamidronate for metastatic bone disease. Ann Oncol 8:1243–1250

    Article  PubMed  CAS  Google Scholar 

  74. Vogel CL, Yanagihara RH, Wood AJ, Schnell FM, Henderson C, Kaplan BH, Purdy MH, Orlowski R, Decker JL, Lacerna L, Hohneker JA (2004) Safety and pain palliation of zoledronic acid in patients with breast cancer, prostate cancer, or multiple myeloma who previously received bisphosphonate therapy. Oncologist 9:687–695

    Article  PubMed  CAS  Google Scholar 

  75. Wardley A, Davidson N, Barrett-Lee P, Hong A, Mansi J, Dodwell D, Murphy R, Mason T, Cameron D (2005) Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration. Br J Cancer 92:1869–1876

    Article  PubMed  CAS  Google Scholar 

  76. Weinfurt KP, Castel LD, Li Y, Timbie JW, Glendenning GA, Schulman KA (2004) Health-related quality of life among patients with breast cancer receiving zoledronic acid or pamidronate disodium for metastatic bone lesions. Med Care 42:164–175

    Article  PubMed  Google Scholar 

  77. Weinfurt KP, Li Y, Castel LD, Saad F, Timbie JW, Glendenning GA, Schulman KA (2005) The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer. Ann Oncol 16:579–584

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

The authors thank Dr. Colin Johnson, Chair of EORTC Quality of Life Module Development, and Dr. Andrew Bottomley, Head of the EORTC Quality of Life Unit, for use of the EORTC QLQ-BM22 module (Table 2). The module is provisional, currently undergoing phase III international validation, and is subject to change based on phase III results. Funding for medical editorial assistance was provided by Novartis Pharmaceuticals Corporation. We thank Tamalette Loh, PhD, ProEd Communications, Inc.®, for her medical editorial assistance.

Author information

Authors and Affiliations

  1. Instituto de Medicina Molecular-Lisboa, Servico de Oncologia, Hospital de Santa Maria, Av Professor Egaz Moniz, Lisbon, 1649-039, Portugal

    Luis Costa

  2. Health Economics and Outcomes Research, Doctor Ferran 25, 2°, Barcelona, 08034, Spain

    Xavier Badia

  3. Radiation Oncology, Toronto-Sunnybrook Regional Cancer Centre, 2075 Bayview Ave., Toronto, ON, M4N 3M5, Canada

    Edward Chow

  4. Milton S. Hershey Medical Center, Pennsylvania State University, 500 University Drive, Hershey, PA, 17033, USA

    Allan Lipton

  5. Cancer Research Department of Medical Oncology, Christie Hospital NHS Foundation Trust, 550 Wilmslow Road, Manchester, M20 4BX, UK

    Andrew Wardley

Authors
  1. Luis Costa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xavier Badia
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Edward Chow
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Allan Lipton
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Andrew Wardley
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Luis Costa.

Additional information

An erratum to this article can be found at http://dx.doi.org/10.1007/s00520-008-0496-z

Rights and permissions

Reprints and permissions

About this article

Cite this article

Costa, L., Badia, X., Chow, E. et al. Impact of skeletal complications on patients’ quality of life, mobility, and functional independence. Support Care Cancer 16, 879–889 (2008). https://doi.org/10.1007/s00520-008-0418-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00520-008-0418-0

Keywords

Search

Navigation